Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Li, Xueqian; Zhou, MengChu; Qi, Jiaqian; Han, Yue

doi:10.1016/j.clml.2020.12.008

Cited by 4 publications

(5 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these studies considered both patients with acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma and did not compare the outcomes with conventional chemotherapy therapy. 41,42 Moreover, other types of CD-targeted immunotherapy which were not previously conducted were also taken into consideration in our study.…”

Section: Discussionmentioning

confidence: 99%

“…Through the pooled analysis, we found that the use of immunotherapy as a part of the induction or salvage therapy also increased the odds of obtaining CR and MRD negativity while reducing the odds of acquiring febrile neutropenia. According to the previously published meta-analyses, blinatumomab 41 and InO 42 are effective for acute lymphoblastic leukemia with limited toxicity. However, these studies considered both patients with acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma and did not compare the outcomes with conventional chemotherapy therapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Ponvilawan

Vittayawacharin

Tunsing

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Buy / Rent full text

Background: Monoclonal antibodies targeting cluster of differentiation (CD) proteins have been incorporated into standard treatments for multiple types of hematologic malignancies, including acute lymphoblastic leukemia (ALL). This systematic review and meta-analysis investigated the efficacy of using CD-targeted antibodies for ALL. Materials and Methods: The EMBASE and MEDLINE databases were searched for research papers using immunotherapy- and ALL-related terms from inception to July 2021. Eligible studies were randomized, controlled trials (RCTs) or cohort studies in which ALL patients received CD-targeted immunotherapy or conventional chemotherapy as the induction or salvage therapy. The reports had to report our primary outcomes of interest: overall survival (OS), relapse-free survival (RFS), or complete remission (CR), with the patient number for each outcome. The effect estimates with 95% confidence interval (CI) from each study were combined to calculate the pooled-effect estimate, using the Hantel-Maenszel method. Results: Five RCTs and 9 retrospective cohort studies were eligible for the meta-analysis. ALL patients given CD-targeted immunotherapy in the induction or salvage therapy had significantly higher OS and RFS rates than those administered conventional chemotherapy only, with pooled odds ratios (OR) of 2.11 (95% CI, 1.76-2.53; I2, 0%) and 2.25 (95% CI, 1.62-3.14; I2, 61%), respectively. The rates of achieving CR and minimal residual disease negativity were also higher for the immunotherapy group, with pooled ORs of 1.70 (95% CI, 1.07-2.69; I2, 79%) and 2.98 (95% CI, 1.17-7.58; I2, 90%), while developing less risk for febrile neutropenia (pooled OR, 0.22; 95% CI, 0.08-0.58; I2, 84%). Subgroup analyses revealed that all antibody types yielded dramatically better OS rates than those for patients administered chemotherapy alone. Conclusions: The ALL patients receiving CD-targeted immunotherapy as induction or salvage therapy had significantly higher response rates and survival outcomes, as well as lower odds of acquiring febrile neutropenia, than the patients given conventional chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Ponvilawan

Vittayawacharin

Tunsing

et al. 2021

Technol Cancer Res Treat

View full text Add to dashboard Buy / Rent full text

show abstract

“…Inotuzumab ozogamicin (InO) is a humanized anti-CD22 antibody combined with the alkylating agent calicheamicin used in the treatment of R/R ALL and NHLs. Release of calicheamicin into lysosomes in the cytoplasmic cell leads to double-stranded DNA cleavage and subsequent cell apoptosis [20,21]. However, the direct toxic effect of the antibiotic is suspected of damaging liver cells, contributing to the inhibition of sinusoidal flow.…”

Section: Inotuzumabmentioning

confidence: 99%

“…Additionally, bilirubin and transaminase levels should be monitored during InO therapy. According to studies in which defibrotide improved survival rates in patients with veno-occlusive disease (VOD), it is believed that defibrotide may be an effective agent in the treatment of VOD [21]. In order to reduce the toxicity of the drug, it is worth avoiding nephrotoxic and hepatotoxic drugs such as azoles, prophylactically using ursodeoxycholic acid and considering combination therapy [1].…”

Section: Inotuzumabmentioning

confidence: 99%

See 1 more Smart Citation

Adverse events of monoclonal antibodies use in therapy of hematological malignancies

Maksymowicz

Podhorecka

2022

Hematology in Clinical Practice

View full text Add to dashboard Buy / Rent full text

Monoclonal antibodies given as monotherapy or combination therapy have emerged as effective treatment options for hematologic malignancies. By prolonging survival, mAbs reduced mortality and improved the clinical prognosis for patients with these diseases. However, despite the effective anticancer activity of mAbs, they induce adverse events. The most common side effects are infusion related reactions (IRR), associated with cytokine release within the first few hours after administration. IRR are usually mild to moderate and manifest in rash, fever, nausea, vomiting, dizziness, headache, hypotension or tachycardia. Other, common toxicities are cytopenias, increasing the risk of infections and bleeding. Most preventive strategies involve the use of glucocorticosteroids, acetaminophen, antihistamines, screening for antibodies against microorganisms and prophylaxis for infections. Cytokine release syndrome, cardiac, pulmonary, neurologic adverse effects occur less frequently. In cases of grade 1-2 toxicity, symptomatic management is recommended, but in more severe symptoms temporary or permanent discontinuation of therapy and use of glucocorticosteroids are recommended. In an effort to limit the incidence and severity of adverse events clinicians should know how to early recognize, precisely assess and timely manage.

show abstract

Efficacy and Safety of Inotuzumab Ozogamicin (CMC-544) for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis

Cited by 4 publications

References 44 publications

Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Efficacy of Targeted Immunotherapy as Induction or Salvage Therapy in Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis

Adverse events of monoclonal antibodies use in therapy of hematological malignancies

Contact Info

Product

Resources

About